The landscape of medical device regulation in the United States is undergoing a quiet but consequential transformation. While the U.S. Food and Drug Administration (FDA) continues to grant clearance for thousands of devices each year, the nature of those clearances—and the strategies companies employ to obtain them—is shifting markedly. Recent data and expert commentary suggest that 510(k) clearances are no longer a one-size-fits-all gateway, as the agency adapts to a flood of software-driven products, decentralized clinical trials, and international harmonization pressures.

A Record Year, But a Changing Mix

According to the FDA’s own Center for Devices and Radiological Health (CDRH) annual report released in late 2025, the agency cleared 3,487 devices via the 510(k) pathway in the fiscal year ending September 30—a modest 4% increase over the prior year. However, the composition of those clearances tells a more nuanced story. Traditional hardware devices—orthopedic implants, cardiovascular catheters, and surgical instruments—still dominate in raw numbers. Yet the fastest-growing segment is software as a medical device (SaMD), which now accounts for roughly 18% of all 510(k) submissions, up from 9% just five years ago.

“We are seeing a fundamental rebalancing,” said Dr. Elena Vasquez, a regulatory affairs consultant and former CDRH reviewer who now advises startups in the digital therapeutics space. “The FDA is not slowing down, but it is applying a more granular, risk-based lens. A simple algorithm update for a glucose monitoring app does not get the same level of scrutiny as a new spinal screw. Companies that fail to recognize that distinction are wasting time and capital.”

Dr. Vasquez points to the FDA’s 2024 final guidance on “Predicate Change and Modification of a Device” as a pivotal document. The guidance clarified when a change to an existing cleared device requires a new 510(k) submission—a question that has long plagued manufacturers. Under the new framework, software changes that are “limited to bug fixes or minor user interface improvements” may not trigger a new submission, provided the manufacturer documents the risk assessment. This has accelerated time-to-market for iterative digital products, but it has also created a compliance trap: companies that over-interpret the flexibility risk enforcement actions.

The AI Predicament: Clearing the Unclearable

Perhaps the most contentious issue in FDA clearance today involves artificial intelligence and machine learning (ML) models that can adapt post-market. The traditional 510(k) paradigm assumes a fixed, deterministic device. An AI model that continuously learns from real-world patient data does not fit that mold. The FDA has responded with a “Predetermined Change Control Plan” (PCCP) framework, first piloted in 2023 and formally codified in draft guidance issued in July 202 5.

Under the PCCP, a manufacturer can seek clearance for an AI algorithm with pre-specified boundaries for future autonomous updates. For example, a chest X-ray triage tool might be cleared to adjust its sensitivity threshold within a defined range without requiring a new submission, as long as the performance metrics remain within the validated envelope. Industry reaction has been cautiously optimistic.

“The PCCP is a pragmatic compromise, but it is not a free pass,” noted Mark Chen, vice president of regulatory at a major imaging analytics firm that received one of the first PCCP-based clearances in September 2025. “We had to prove not only that our algorithm was safe and effective at launch, but that our change control process itself was robust. That means continuous monitoring, real-world data collection, and a transparent audit trail. The FDA is effectively clearing a governance framework, not just a piece of software.”

Chen’s experience reflects a broader trend: the FDA is increasingly evaluating themanufacturer’s quality systemas much as the device itself. This shift is visible in the agency’s increased use of “special 510(k)s” and “abbreviated 510(k)s,” which rely on consensus standards or design verification rather than full clinical data. In FY2025, abbreviated submissions accounted for 41% of all clearances, up from 33% in FY2020.

Global Divergence and the Shadow of EU MDR

While the FDA has moved toward flexibility, its European counterpart is moving in the opposite direction. The full implementation of the EU Medical Device Regulation (MDR) has created a bottleneck, with many small and mid-sized U.S. companies choosing to prioritize FDA clearance over CE marking. This divergence has a subtle but real impact on FDA strategy.

“We are seeing companies submit to the FDA first, not because the U.S. market is more attractive, but because the regulatory path is more predictable,” said Dr. Vasquez. “The EU’s Notified Bodies are swamped, and the requirements for clinical evaluation are more onerous under MDR. The FDA, by contrast, has maintained a 90-day review target for 510(k)s and has been transparent about its decision-making. That predictability is valuable.”

However, the FDA is not immune to criticism. The agency’s reliance on predicate devices—older products that serve as the basis for substantial equivalence—has come under renewed scrutiny. A 2025 analysis by the nonprofit ECRI Institute found that 78% of 510(k) clearances in the last two years referenced predicates that were themselves cleared more than a decade ago. This “predicate creep” raises questions about whether incremental innovation is being rewarded at the expense of true novelty.

The FDA has acknowledged this concern. In a November 2025 public workshop, CDRH Director Dr. Michelle Tarver stated, “We are exploring a more modern framework for substantial equivalence that accounts for the risk profile of the new device, not just its similarity to an older one. But we cannot abandon the 510(k) pathway without a viable alternative, and that alternative does not yet exist.”

De Novo and Breakthrough: The High-Risk, High-Reward Lane

For truly novel devices with no predicate, the De Novo pathway remains the only route to clearance. In FY2025, the FDA granted 87 De Novo authorizations, a record high. Notably, over half of those were for digital health products, including wearable seizure monitors, AI-based sepsis prediction software, and a novel smartphone-based retinal imaging system.

The Breakthrough Devices Program, which expedites review for technologies that offer significant advantages over existing alternatives, also saw increased activity. The agency designated 92 new Breakthrough devices in FY2025, and the median time to clearance for Breakthrough-designated 510(k)s was 142 days, compared to 189 days for standard submissions.

Yet experts warn that Breakthrough status is not a shortcut to commercial success. “Breakthrough gives you priority review and more interactive communication with the FDA, but it does not lower the evidentiary bar,” said Chen. “In fact, because these devices are often first-in-class, the FDA may ask for more robust real-world evidence or post-market surveillance commitments. You need to have a full data strategy from day one.”

Looking Ahead: The 2026 User Fee Agreement and Beyond

The next major inflection point will be the reauthorization of the Medical Device User Fee Amendments (MDUFA) for fiscal years 2028–2032, with negotiations commencing in early 2026. Industry groups, including AdvaMed and the Medical Device Manufacturers Association (MDMA), have already signaled their priorities: faster review for software updates, more predictable De Novo timelines, and a formal pathway for “adaptive” devices that change based on user feedback.

The FDA, for its part, is piloting a “total product lifecycle” approach, where clearance is viewed as the beginning, not the end, of regulatory oversight. This includes expanded use of real-world data (RWD) collected from electronic health records and patient registries. In a recent Federal Register notice, the agency proposed a framework for using RWD to support post-market surveillance commitments for AI devices—a move that could reduce the burden of traditional prospective studies.

For manufacturers, the strategic implications are clear. The era of “submit a 510(k) and forget it” is over. Successful clearance now requires a narrative that addresses not only safety and efficacy at the moment of launch but also the device’s evolution over time. Companies that embed regulatory thinking into their design process—rather than treating it as a final hurdle—will be the ones that thrive.

As Dr. Tarver put it during the November workshop: “FDA clearance is not a trophy. It is a contract with the American public that a device is safe and effective—not just on day one, but for the life of the product. We are building the tools to enforce that contract, and we expect industry to build the systems to honor it.”

With the digital health boom showing no signs of abating, and the FDA’s own regulatory toolkit expanding, the coming year will likely see further refinement of the 510(k) pathway—and new debates over how to balance innovation, access, and safety. For now, the message from regulators and industry veterans alike is consistent: the rules are changing, and the winners will be those who read the fine print early.